immune response genes

ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with nanomolar binding affinities to the bromodomains (BDs) of BRD4, exhibiting IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

2'2'-cGAMP is a synthetic dinucleotide (CDN) that contains non-canonical 2'5'-phosphodiester bonds. It binds to the adapter protein stimulator of interferon genes , which is a component of the innate immune response that activates the type I interferon pathway when bound to cyclic dinucleotides. 2'2-cGAMP shows weaker binding to STING than 2'3'-cGAMP but binds more strongly than 3'3'-cGAMP , cyclic di-GMP , or 3'2'-cGAMP, which bind in the micromolar range (Kds = 1.04, 1.21, or 1.61 μM, respectively). Despite weaker binding, 2'2'-cGAMP induces IFN-β production in the same concentration range as 2'3'-cGAMP (EC50s = 15.8 and 19.4 nM, respectively, in L929 cells).

BSP16 is a highly potent, orally active stimulator of the interferon gene (STING) agonist that selectively activates the STING pathway, induces the production of type I interferons (IFNs) and pro-inflammatory cytokines, and elicits a systemic antitumor immune response. BSP16 is intended for use in cancer research.

NFAT:AP-1 inhibitor-10 is a novel inhibitor of the NFAT:AP-1:DNA interaction on the ARRE-2 element, binding to DNA in a sequence-selective manner and inhibiting the transcription of the Il2 gene and several other cyclosporin A-sensitive cytokine genes important for the effector immune response.

Dexamethasone sodium succinate is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide......

CDN-A, a cyclic di-nucleotide, serves as a precursor for synthesizing antibody-drug conjugates (ADC) and acts as a potent stimulator of both innate and adaptive immune responses. In humans, these cyclic di-nucleotides, produced endogenously in response to foreign DNA or by bacterial pathogens, activate the innate immune system by inducing the expression of interferon genes [1] [2] [3].

SNX281, an interferon gene (STING) agonist, enhances the cGAS-STING signaling pathway by binding to the STING protein, thereby boosting the immune response against tumor cells. SNX281 is primarily used in cancer immunology research.

Cyclic GMP (cGMP) belongs to the class of endogenous metabolites and is a pivotal intracellular second messenger that mediates extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). The effects of Cyclic GMP are primarily executed through three main target groups: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and phosphodiesterases (PDEs). Cyclic GMP is capable of inhibiting platelet adhesion and aggregation and participates in enhancing antiviral immune responses.

Cyclic GMP TBAOH is an endogenous second messenger that triggers the production of interferons in response to cytosolic DNA. It activates the stimulator of interferon genes (STING), initiating a signaling cascade that produces type I interferons and other immune mediators. The conjugate of Cyclic GMP TBAOH and AMP, known as Cyclic-GMP-AMP, can induce IRF3 phosphorylation and nuclear translocation to enhance antiviral immune responses. Additionally, Cyclic GMP TBAOH may activate PDE to degrade cAMP, inhibit the calcium current ICa in cardiomyocytes, and regulate myocardial contractility. Its derivative, 8-Br-cGMP, exhibits antiplatelet activity, making Cyclic GMP TBAOH useful for research in antiviral immunity and cardiovascular diseases.

dCNP binds to NPR-B/C receptors (NPR-B/C receptor), initiating the cGMP signaling pathway and regulating vascular function. It exhibits anti-hypoxic effects by downregulating hypoxia-related genes such as HIF1α and HIF2α. Additionally, dCNP inhibits tumor stroma induction, demonstrating antifibrotic properties. It also enhances immune response by upregulating CTL, NK cells, and conventional type 1 dendritic cells in tumors.